Evidence map›Paper›PMID 25920395›Full record

ArticleJapanese journal of clinical oncology2015

Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.

Sailaja Kagita, Srihari Uppalapati, Sadasivudu Gundeti, Raghunadharao Digumarti

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. C/EBPα RegulatesInsects · 2022
    Article
  3. The Hidden Pathogenesis of CML: Is BCR-ABL1 the First Event?Current hematologic malignancy reports · 2019
    Review
  4. Article
  5. Essential genes of the macrophage response toCellular & molecular biology letters · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Sailaja KagitaDepartment of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Andhra Pradesh.
Srihari UppalapatiDepartment of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Andhra Pradesh.
Sadasivudu GundetiDepartment of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Andhra Pradesh.
Raghunadharao DigumartiDepartment of Medical Oncology, Nizams Institute of Medical Sciences, Hyderabad, Andhra Pradesh Homi Bhabha Cancer Hospital and Research Centre, Visakapatnam, Andhra Pradesh, India rdigumarti@gmail.com.
Nizam's Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveAltered differentiation is a common feature of haematopoietic malignancies with poor prognosis. CAAT/enhancer binding protein alpha (C/EBPα) is a key transcription factor that regulates myeloid differentiation. This study is aimed to know the prognostic value of CAAT/enhancer binding protein alpha expression and correlate its expression with response to imatinib therapy.

methodsWe quantified the expression of C/EBPα gene in 126 chronic myeloid leukaemia samples (82 from newly diagnosed and 44 from imatinib-resistant patients) and 20 control samples. C/EBPα mRNA level was measured by real-time quantitative polymerase chain reaction using the ΔΔCT method.

resultsC/EBPα expression level was significantly lower in the imatinib-resistant group than in the pretreatment and control group (P = 0.0398). Low CAAT/enhancer binding protein alpha levels in the imatinib-resistant group were significantly associated with advanced phase (P = 0.04), with more peripheral blasts (P = 0.0001), high BCR-ABL levels (P = 0.018) and T315I and P-loop mutations (P = 0.0002). In the pretreatment group, low expression showed association with high EUTOS risk score (P = 0.03) and possible partial cytogenetic response (P = 0.010).

conclusionsOur results suggest that low expression of CAAT/enhancer binding protein alpha might have a role in the response to imatinib and progression of disease in patients with chronic myeloid leukaemia.

Indexed as

Drug Resistance, NeoplasmAdultAgedAntineoplastic AgentsBenzamidesCCAAT-Enhancer-Binding Protein-alphaCell DifferentiationFemaleFusion Proteins, bcr-ablHumansImatinib MesylateIsoleucineLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMiddle AgedMutationAntineoplastic AgentsBenzamidesCCAAT-Enhancer-Binding Protein-alphaFusion Proteins, bcr-ablImatinib MesylateIsoleucinePiperazinesPyrimidinesThreonineBCR-ABL TK mutationsC/EBPαchronic myeloid leukaemiaexpressionimatinibresponse

Identifiers

PMID25920395
OpenAlexW2144330572

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.